30.83 USD
+0.07 (+0.23%)
30.83 USD
0 (0%)
Overall TGTX gets a fundamental rating of 5 out of 10. We evaluated TGTX against 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year TGTX was profitable.
TGTX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
TGTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 43.65%, TGTX belongs to the top of the industry, outperforming 99.06% of the companies in the same industry.
With an excellent Return On Equity value of 73.69%, TGTX belongs to the best of the industry, outperforming 99.25% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.35%, TGTX belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.69% | ||
| ROIC | 9.35% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of TGTX (84.13%) is better than 98.49% of its industry peers.
The Operating Margin of TGTX (19.32%) is better than 94.35% of its industry peers.
TGTX's Gross Margin of 85.34% is amongst the best of the industry. TGTX outperforms 87.57% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.32% | ||
| PM (TTM) | 84.13% | ||
| GM | 85.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TGTX is creating some value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
Compared to 1 year ago, TGTX has a worse debt to assets ratio.
2.2 Solvency
TGTX has an Altman-Z score of 6.87. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TGTX (6.87) is better than 76.27% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that TGTX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.40, TGTX is doing worse than 71.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.87 |
ROIC/WACC1.07
WACC8.77%
2.3 Liquidity
A Current Ratio of 3.82 indicates that TGTX has no problem at all paying its short term obligations.
With a Current ratio value of 3.82, TGTX perfoms like the industry average, outperforming 45.01% of the companies in the same industry.
TGTX has a Quick Ratio of 2.89. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Quick ratio of 2.89. This is in the lower half of the industry: TGTX underperforms 64.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 563.64% over the past year.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 100.88%.
The Revenue has been growing by 364.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
3.2 Future
TGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 92.99% yearly.
Based on estimates for the next years, TGTX will show a very strong growth in Revenue. The Revenue will grow by 40.43% on average per year.
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 60.45, which means the current valuation is very expensive for TGTX.
90.58% of the companies in the same industry are more expensive than TGTX, based on the Price/Earnings ratio.
TGTX is valuated expensively when we compare the Price/Earnings ratio to 26.34, which is the current average of the S&P500 Index.
TGTX is valuated correctly with a Price/Forward Earnings ratio of 16.53.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, TGTX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.45 | ||
| Fwd PE | 16.53 |
4.2 Price Multiples
TGTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TGTX is cheaper than 90.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 48.04 |
4.3 Compensation for Growth
TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX has a very decent profitability rating, which may justify a higher PE ratio.
TGTX's earnings are expected to grow with 157.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y265.02%
EPS Next 3Y157.07%
5. Dividend
5.1 Amount
No dividends for TGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.83
+0.07 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.63%
Inst Owner Change-3.01%
Ins Owners6.78%
Ins Owner Change-24.45%
Market Cap4.89B
Revenue(TTM)531.90M
Net Income(TTM)447.47M
Analysts78.67
Price Target45.17 (46.51%)
Short Float %17.05%
Short Ratio13.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.98%
Min EPS beat(2)-28.7%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-14.65%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)3
Avg EPS beat(8)0.93%
EPS beat(12)5
Avg EPS beat(12)39.18%
EPS beat(16)8
Avg EPS beat(16)34.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)4.19%
Revenue beat(4)3
Avg Revenue beat(4)1.06%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)4.47%
Revenue beat(12)9
Avg Revenue beat(12)25.49%
Revenue beat(16)11
Avg Revenue beat(16)25.09%
PT rev (1m)2.59%
PT rev (3m)5.44%
EPS NQ rev (1m)0.95%
EPS NQ rev (3m)-22.81%
EPS NY rev (1m)277.08%
EPS NY rev (3m)264.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.54%
Revenue NY rev (1m)3.05%
Revenue NY rev (3m)2.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.45 | ||
| Fwd PE | 16.53 | ||
| P/S | 9.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.06 | ||
| P/tB | 8.06 | ||
| EV/EBITDA | 48.04 |
EPS(TTM)0.51
EY1.65%
EPS(NY)1.87
Fwd EY6.05%
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS3.35
BVpS3.82
TBVpS3.82
PEG (NY)0.03
PEG (5Y)N/A
Graham Number6.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.69% | ||
| ROCE | 11.84% | ||
| ROIC | 9.35% | ||
| ROICexc | 11.02% | ||
| ROICexgc | 11.02% | ||
| OM | 19.32% | ||
| PM (TTM) | 84.13% | ||
| GM | 85.34% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score5
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 357.45% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 | ||
| Altman-Z | 6.87 |
F-Score5
WACC8.77%
ROIC/WACC1.07
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
EBIT growth 1Y20452.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year378.75%
EBIT Next 3Y148.94%
EBIT Next 5YN/A
FCF growth 1Y-66.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.55%
OCF growth 3YN/A
OCF growth 5YN/A
TG THERAPEUTICS INC / TGTX FAQ
What is the fundamental rating for TGTX stock?
ChartMill assigns a fundamental rating of 5 / 10 to TGTX.
Can you provide the valuation status for TG THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.
Can you provide the profitability details for TG THERAPEUTICS INC?
TG THERAPEUTICS INC (TGTX) has a profitability rating of 6 / 10.
What are the PE and PB ratios of TG THERAPEUTICS INC (TGTX) stock?
The Price/Earnings (PE) ratio for TG THERAPEUTICS INC (TGTX) is 60.45 and the Price/Book (PB) ratio is 8.06.
How financially healthy is TG THERAPEUTICS INC?
The financial health rating of TG THERAPEUTICS INC (TGTX) is 4 / 10.